Cannabis Science Inc.
Cannabis Science Inc.
Home
About Us
Corporate Overview
Mission Statement
Cannabis Science Team
Careers & Corporate Culture
iCannabinoid
Join Now!
R&D
The Science of Cannabinoids
CBIS Cannabinoid Research
Critical Ailments
COLLABORATIONS & PROJECTS
CBIS Medical Consortium
Global Economic Development
Pan African A & C University
African Economic Initiative
American States University
North American Economic Initiative
Dana-Farber
CFA
Stellenbosch University
CBIS Bottle It
Products & Pharmacies
Products
Order Online
Pharmacies
Investors
CBIS Current Share Structure
SEC Filings
Media
CBIS News Releases
CBIS In The News
CBIS Events
Contact
latest Articles
Cannabis Science Issues 2019 Guidance Report; Under SEC Sanctions the Company Goes Private as It Enters Into Step (2) of Its Growth Transition, Enabling Full Transparency and Revenue Growth
Cannabis Science Enters Transition Stage as Trading of the Company’s Shares is Halted; The Company Will Continue to Implement Its Growth Strategy and Resolve All Outstanding Fully Reporting Requirements
Cannabis Science Partners With CDN Firm NHS Industries to Launch the CBIS CDN Economic Development Plan; CBIS to Use Its Relations With the Harvard International Phytomedicines and Medical Cannabis Institute and Other Leading Institutions
Cannabis Science Prepares Announcements for Revenues and Corporate Growth; Finalizing New Asset Partnerships and Acquisitions Targeting Positive Cash Flow in Key Markets Globally
Cannabis Science Successfully Completes European Headquarters and Operations Move to The Netherlands and Completes Shut Down of All Cannabis Science Europe GmbH Germany Operations
CBIS LATEST NEWS.
Home
2016
2018
-
2017
-
2016
-
2015
-
2014
-
2013
-
2012
-
2011
-
2010
-
2009
Warning
: Creating default object from empty value in
/home/cannabisscience/public_html/plugins/system/t3/base-bs3/html/com_content/category/default_articles.php
on line
17
Title
Published Date
Cannabis Science Expands Clinical Studies to Include Selected Patients for Asthma, Several Important Pain Targets, and Sleep Deprivation With Additional Medications
13-09-16
Cannabis Science Receives Initial Batch of Nebulizers for CBIS MDI Rescue Inhalers Targeting Asthma/COPD; Prepares Packaging & Distribution
06-09-16
Cannabis Science Activates Its Critical Financial Security Department to Specialize in the Worldwide Industry Deficiency in Risk Mitigation, Banking, Payment Processing, and Cash and Asset Movement
02-09-16
Cannabis Science and the Research Foundation Begins Protocols for California Legal Patients to Receive the New CBIS MDI Rescue Inhaler for Its First Observational Study Intending to Lead Into Clinical Trials
12-08-16
Cannabis Science Orders First Batch Inhalation Medication and Adds CBIS MDI Rescue Inhaler for Asthma/COPD via Nebulizer, Targeting 25+ Legal States, and National Market Variables
11-08-16
Twenty Acre Indoor/Outdoor Cultivation Facility in Northern California in the Final Stages of Escrow Awaiting Transfer of Ownership to Cannabis Science, Inc.
01-08-16
Cannabis Science Develops Inhalation Medication for Those Suffering Asthma/COPD via Nebulizer, Targets National Markets
29-07-16
Cannabis Science 2016 Growth Guidance; Project Briefs, Cash-Flow Projections, and Current Historic Cannabis Industry Advancements; Industry Growth Indicators
20-07-16
CFA Announces That the 2016 Ronald H. Brown African Affairs Series Will Be a Bipartisan Forum to Develop Policy Recommendations for the Next U.S. Presidential Administration
18-07-16
CBIS CEO, Mr. Raymond C. Dabney, Invited to Serve as Co-Chair of the Constituency for Africa's 2016 Ronald H. Brown African Affairs Series in September
11-07-16
Start
Prev
1
2
3
4
5
6
7
Next
End